About

A Pipeline to Change Conventional Anti-Cancer Therapies

A Pipeline to Change Conventional Anti-Cancer Therapies

At Aptose Biosciences, we are building a pipeline of novel and targeted oncology therapies with the potential to serve specific populations of cancer patients.

Our pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of conventional anti-cancer therapies through simultaneous targeting of key drivers of disease in cancer cells without overlapping toxicities and thus preserving the quality of life in cancer patients.

View Pipeline

Clinical Trials

We have two clinical-stage investigational products for hematologic malignancies.

View Clinical Trials
Phase 1 Study of CG-806 in CLL & NHL
Phase 1 Study of CG-806 in CLL & NHL

CG-806, an oral, mutation-agnostic FLT3/BTK inhibitor, is in a Phase 1 study in patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL).

View Clinical Trials
Phase 1a/b Study of CG-806 in AML
Phase 1a/b Study of CG-806 in AML

CG-806, an oral, mutation-agnostic FLT3/BTK inhibitor, is in a Phase 1a/b study in patients with relapsed or refractory acute myeloid leukemia (AML).

View Clinical Trials
Phase 1b Study of APTO-253 in AML & MDS
Phase 1b Study of APTO-253 in AML & MDS

APTO-253, the only clinical-stage agent that directly targets the MYC oncogene and inhibits its expression, is in a Phase 1b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including AML and high-risk MDS.

View Clinical Trials
Our Leadership Team

Our Leadership Team

Our leadership team is comprised of distinguished individuals who possess an actionable blend of academic and industry experience, having served in numerous leadership roles throughout their careers.